{"id":15946,"date":"2026-09-03T06:00:00","date_gmt":"2026-09-03T10:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=15946"},"modified":"2026-09-01T10:16:24","modified_gmt":"2026-09-01T14:16:24","slug":"when-the-virus-leaves-but-the-darkness-remains","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=15946","title":{"rendered":"When the Virus Leaves, but the Darkness Remains"},"content":{"rendered":"\n

COVID-19, Long COVID, and the Biology of Persistent Depression<\/strong><\/h4>\n\n\n\n

John Murphy, CEO The COVID-19 Long haul Foundation<\/p>\n\n\n\n

Introduction: A Depression That May Not Begin in the Mind<\/h5>\n\n\n\n

Among the many consequences of SARS-CoV-2 infection, depression is perhaps one of the most misunderstood.<\/p>\n\n\n\n

The conventional story of depression is familiar: a person becomes ill, loses a job, suffers bereavement, becomes socially isolated, or develops another chronic disease, and psychological distress follows. There is undoubtedly a substantial psychosocial component to depression after COVID-19. The pandemic itself produced extraordinary isolation, bereavement, financial insecurity and fear.<\/p>\n\n\n\n

But that explanation becomes increasingly inadequate when one considers the experience of people with Long COVID.<\/p>\n\n\n\n

Some patients who were previously psychologically healthy describe a profound alteration in mood weeks or months after the acute infection has apparently resolved. They may lose interest in things that once mattered to them. Sleep becomes disordered. Concentration deteriorates. Pleasure disappears. Energy becomes almost nonexistent. The future seems inaccessible. Some describe emotional numbness rather than sadness.<\/p>\n\n\n\n

And, importantly, these symptoms often occur in conjunction with abnormalities that are unmistakably physiological: autonomic dysfunction, cognitive impairment, neuropathy, sleep disruption, inflammatory abnormalities, altered cortisol physiology, metabolic disturbances, impaired cerebral perfusion and, in some patients, measurable changes in white- and gray-matter structure.<\/p>\n\n\n\n

The emerging scientific picture therefore suggests that depression following COVID-19 is not necessarily a single disorder. It is more plausibly a heterogeneous neuropsychiatric syndrome produced by several interacting pathways<\/strong>, some biological and some psychological.<\/p>\n\n\n\n

A 2025 systematic review and meta-analysis encompassing 94 studies found a pooled prevalence of depression of approximately 25% among people with Long COVID<\/strong>, with substantial heterogeneity between studies. Importantly, depression and\/or anxiety remained common even two years after infection, although prevalence generally declined over time.\u00b9<\/p>\n\n\n\n

Another large systematic review involving more than 7.7 million participants estimated depression or anxiety in approximately 23%<\/strong> of people with post-COVID syndrome.\u00b2<\/p>\n\n\n\n

The phenomenon is therefore neither rare nor trivial.<\/p>\n\n\n\n

The deeper question is not simply how many Long COVID patients become depressed?<\/em><\/p>\n\n\n\n

It is:<\/p>\n\n\n\n

What has happened to the brain, immune system, endocrine system and metabolism that can make depression persist long after the virus itself is no longer detectable in the respiratory tract?<\/strong><\/p>\n\n\n\n

\n\n\n\n
I. The Epidemiology of the Post-COVID Depressive State<\/h5>\n\n\n\n

The prevalence estimates vary dramatically because investigators have studied different populations, used different diagnostic instruments and examined patients at different points in recovery.<\/p>\n\n\n\n

Nevertheless, several broad patterns have emerged.<\/p>\n\n\n\n

A meta-analysis of longitudinal cohort studies examining COVID survivors over two years found depression prevalence of approximately:<\/p>\n\n\n\n

Time after infection<\/th>Pooled depression prevalence<\/th><\/tr>
0\u20131 month<\/td>22%<\/strong><\/td><\/tr>
1\u20133 months<\/td>19%<\/strong><\/td><\/tr>
3\u20136 months<\/td>21%<\/strong><\/td><\/tr>
6\u201312 months<\/td>15%<\/strong><\/td><\/tr>
12\u201324 months<\/td>9%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The decline is reassuring, but it is not linear. Depression can temporarily increase several months after infection before subsequently declining.\u00b3<\/p>\n\n\n\n

This distinction matters.<\/p>\n\n\n\n

A patient who remains depressed at six months is not necessarily following a simple trajectory toward recovery. Long COVID frequently behaves as a relapsing-remitting illness<\/strong>. Symptoms may improve substantially and then return following exertion, another infection, hormonal changes, sleep disruption or an apparently minor physiological stressor.<\/p>\n\n\n\n

A separate longitudinal study of 239 patients with persistent COVID-related complaints found depressive symptoms in 46.9% at three months<\/strong>, declining only modestly to 40.6% at six months<\/strong>. Anxiety showed a similar pattern, while PTSD symptoms declined more substantially. Notably, the psychiatric burden was similar among hospitalized and non-hospitalized patients.\u2074<\/p>\n\n\n\n

This last observation is particularly important.<\/p>\n\n\n\n

Long COVID depression cannot simply be interpreted as the psychological aftermath of intensive-care hospitalization.<\/p>\n\n\n\n

A person can have a relatively mild acute infection and subsequently develop profound neurological and psychiatric dysfunction.<\/p>\n\n\n\n

Indeed, many people who develop Long COVID were never hospitalized.<\/p>\n\n\n\n

\n\n\n\n
II. Depression Is Not the Same as Being Sad About Having Long COVID<\/h5>\n\n\n\n

The distinction between reactive depression<\/strong> and biologically mediated depression<\/strong> is essential.<\/p>\n\n\n\n

A person with Long COVID can understandably become depressed because:<\/p>\n\n\n\n

    \n
  • employment has been lost;<\/li>\n\n\n\n
  • physical independence has disappeared;<\/li>\n\n\n\n
  • relationships have changed;<\/li>\n\n\n\n
  • friends and physicians may not understand the illness;<\/li>\n\n\n\n
  • ordinary activities become exhausting;<\/li>\n\n\n\n
  • financial circumstances deteriorate;<\/li>\n\n\n\n
  • the future becomes uncertain.<\/li>\n<\/ul>\n\n\n\n

    These circumstances can produce genuine major depression without requiring a neurological explanation.<\/p>\n\n\n\n

    But Long COVID presents another possibility.<\/p>\n\n\n\n

    Depression may occur as part of the same biological process producing fatigue, brain fog, autonomic dysfunction, neuropathy and sleep disturbance<\/strong>.<\/p>\n\n\n\n

    This distinction does not imply that psychological treatment is inappropriate. Quite the contrary. Psychotherapy, social support and antidepressant treatment may be extremely valuable.<\/p>\n\n\n\n

    Rather, it means that telling a patient that depression is merely a psychological reaction to chronic illness may be biologically incorrect and clinically damaging.<\/p>\n\n\n\n

    The emerging evidence suggests that SARS-CoV-2 can alter several biological systems directly implicated in mood regulation.<\/p>\n\n\n\n

    \n\n\n\n
    III. The Neuroinflammatory Brain<\/h5>\n\n\n\n

    The first major hypothesis involves neuroinflammation<\/strong>.<\/p>\n\n\n\n

    During acute COVID-19, the immune system can release large quantities of inflammatory mediators, including interleukins, tumor necrosis factor and interferon-related signaling molecules. In some individuals, inflammatory signaling does not return immediately to its pre-infection state.<\/p>\n\n\n\n

    The brain possesses its own immune system.<\/p>\n\n\n\n

    Microglia\u2014the resident macrophage-like immune cells of the central nervous system\u2014continuously survey neural tissue. Under normal circumstances they maintain synaptic integrity, remove damaged cellular material and help regulate neuronal networks.<\/p>\n\n\n\n

    When persistently activated, however, microglia can become a source of inflammatory signaling, oxidative stress and altered synaptic function.<\/p>\n\n\n\n

    A review in the Journal of Molecular Neuroscience<\/em> proposed a mechanistic connection between COVID-19, oxidative stress, neuroinflammation and depression. The authors described inflammatory activation of the hypothalamic-pituitary-adrenal axis and induction of indoleamine-2,3-dioxygenase, redirecting tryptophan metabolism toward the kynurenine pathway.\u2075<\/p>\n\n\n\n

    This pathway provides a particularly intriguing bridge between systemic infection and psychiatric disease.<\/p>\n\n\n\n

    \n\n\n\n
    IV. The Tryptophan\u2013Kynurenine Pathway: A Biochemical Bridge to Depression<\/h5>\n\n\n\n

    Tryptophan is the precursor of serotonin.<\/p>\n\n\n\n

    But serotonin is not the only destination for tryptophan.<\/p>\n\n\n\n

    During inflammation, the enzyme indoleamine-2,3-dioxygenase can become activated, diverting tryptophan toward kynurenine<\/strong> and its downstream metabolites.<\/p>\n\n\n\n

    In simplified form:<\/p>\n\n\n\n

    Tryptophan \u2192 Kynurenine \u2192 kynurenic acid \/ quinolinic acid and related metabolites<\/strong><\/p>\n\n\n\n

    This matters because some kynurenine metabolites influence glutamate signaling, oxidative stress, neuronal excitability and neuroinflammation.<\/p>\n\n\n\n

    Consequently, inflammation can potentially produce a double effect:<\/p>\n\n\n\n

      \n
    1. less substrate available for serotonin synthesis; and<\/li>\n\n\n\n
    2. greater production of neuroactive metabolites capable of altering neuronal function.<\/li>\n<\/ol>\n\n\n\n

      A 2023 study of Long COVID patients three to ten months after acute infection found a subgroup characterized by markedly reduced tryptophan, increased kynurenine and a higher kynurenine\/tryptophan ratio. This subgroup also had severe fatigue, depression and anxiety.\u2076<\/p>\n\n\n\n

      Another study found depressive symptoms in 32.2% of COVID survivors six months after infection<\/strong>, compared with 6.6% among healthy controls, and linked psychiatric outcomes to abnormalities in the kynurenine pathway.\u2077<\/p>\n\n\n\n

      A 2024 systematic review and meta-analysis involving 1,167 individuals further found evidence of altered tryptophan-catabolite metabolism in Long COVID.\u2078<\/p>\n\n\n\n

      The hypothesis has now moved beyond theoretical speculation.<\/p>\n\n\n\n

      A particularly important 2026 study found that gray-matter volumes in people with long-term post-COVID symptoms were associated with peripheral kynurenine-pathway metabolites and the severity of depressive symptoms. Participants were studied approximately 156 weeks\u2014nearly three years\u2014after infection<\/strong>.\u2079<\/p>\n\n\n\n

      That finding is significant because it connects three previously separate observations:<\/p>\n\n\n\n

      immune-metabolic disturbance \u2192 brain structural change \u2192 depression.<\/strong><\/p>\n\n\n\n

      It does not prove causality, but it substantially strengthens the case for a biological substrate.<\/p>\n\n\n\n

      \n\n\n\n
      V. Serotonin: The Gut\u2013Brain Connection<\/h5>\n\n\n\n

      Perhaps the most provocative mechanistic hypothesis concerns serotonin itself.<\/p>\n\n\n\n

      Research published in Cell<\/em> proposed that persistent viral effects in the gastrointestinal tract and interferon-driven inflammation could reduce circulating serotonin through several mechanisms, including impaired tryptophan absorption, platelet abnormalities and increased serotonin metabolism.<\/p>\n\n\n\n

      The resulting serotonin deficiency could impair vagal signaling and hippocampal function, providing a potential explanation for cognitive impairment and other neurological symptoms of Long COVID.\u00b9\u2070<\/p>\n\n\n\n

      This hypothesis is attractive because it potentially connects several otherwise disconnected systems:<\/p>\n\n\n\n

      gut \u2192 immune system \u2192 serotonin \u2192 vagus nerve \u2192 hippocampus \u2192 cognition and mood.<\/strong><\/p>\n\n\n\n

      It also raises an intriguing therapeutic question concerning selective serotonin reuptake inhibitors.<\/p>\n\n\n\n

      But an important distinction must be made.<\/p>\n\n\n\n

      SSRIs are established treatments for major depression.<\/p>\n\n\n\n

      That does not<\/strong> mean that serotonin deficiency has been conclusively demonstrated to be the cause of Long COVID depression in every patient.<\/p>\n\n\n\n

      The serotonin hypothesis remains an active area of investigation.<\/p>\n\n\n\n

      \n\n\n\n
      VI. White Matter, Myelin and the Architecture of Depression<\/h5>\n\n\n\n

      One of the most striking developments in this field has been the emergence of neuroimaging evidence.<\/p>\n\n\n\n

      Traditional MRI can miss subtle abnormalities of brain tissue. More sophisticated techniques can interrogate myelin and tissue microstructure.<\/p>\n\n\n\n

      A 2024 study specifically examined people with clinically diagnosed post-COVID depression<\/strong> using macromolecular proton fraction mapping, a quantitative MRI method sensitive to myelin-related changes.<\/p>\n\n\n\n

      The investigators found extensive abnormalities involving white matter and several gray-matter structures.<\/p>\n\n\n\n

      Among the affected regions were:<\/p>\n\n\n\n

        \n
      • the inferior fronto-occipital fasciculus;<\/li>\n\n\n\n
      • posterior thalamic radiation;<\/li>\n\n\n\n
      • external capsule;<\/li>\n\n\n\n
      • sagittal stratum;<\/li>\n\n\n\n
      • tapetum;<\/li>\n\n\n\n
      • hippocampus;<\/li>\n\n\n\n
      • putamen;<\/li>\n\n\n\n
      • globus pallidus;<\/li>\n\n\n\n
      • amygdala.<\/li>\n<\/ul>\n\n\n\n

        Most strikingly, abnormalities of the inferior fronto-occipital fasciculus<\/strong> were strongly associated with depression severity measured using the Hamilton Depression Rating Scale.\u00b9\u00b9<\/p>\n\n\n\n

        The finding deserves careful interpretation.<\/p>\n\n\n\n

        It does not mean that SARS-CoV-2 has produced conventional multiple-sclerosis-like demyelination throughout the brain.<\/p>\n\n\n\n

        Rather, it suggests that some patients with post-COVID depression have detectable alterations in the integrity or composition of white matter.<\/p>\n\n\n\n

        The implications are profound.<\/p>\n\n\n\n

        White matter is the communication infrastructure of the brain.<\/p>\n\n\n\n

        Gray matter contains neuronal bodies and local circuits; white matter connects distant regions.<\/p>\n\n\n\n

        A disruption of those connections could potentially interfere with the coordination among the frontal cortex, limbic system, thalamus and other networks involved in motivation, emotional regulation, memory and executive function.<\/p>\n\n\n\n

        The brain can therefore become psychologically dysfunctional without being structurally destroyed.<\/p>\n\n\n\n

        \n\n\n\n
        VII. The Limbic System: Hippocampus, Amygdala and Emotional Regulation<\/h5>\n\n\n\n

        Depression is not localized to one “depression center” in the brain.<\/p>\n\n\n\n

        It is a disorder of interconnected networks.<\/p>\n\n\n\n

        The hippocampus<\/strong> participates in memory, stress regulation and contextual processing.<\/p>\n\n\n\n

        The amygdala<\/strong> participates in emotional salience and threat processing.<\/p>\n\n\n\n

        The prefrontal cortex<\/strong> contributes to executive control and emotional regulation.<\/p>\n\n\n\n

        The anterior cingulate cortex<\/strong> participates in motivation, affect and error processing.<\/p>\n\n\n\n

        The basal ganglia<\/strong> participate in reward, motivation and movement.<\/p>\n\n\n\n

        COVID-related abnormalities in these systems could therefore produce an unusual mixture of symptoms:<\/p>\n\n\n\n

          \n
        • anhedonia;<\/li>\n\n\n\n
        • cognitive slowing;<\/li>\n\n\n\n
        • emotional blunting;<\/li>\n\n\n\n
        • anxiety;<\/li>\n\n\n\n
        • loss of motivation;<\/li>\n\n\n\n
        • impaired memory;<\/li>\n\n\n\n
        • sleep disturbance;<\/li>\n\n\n\n
        • fatigue;<\/li>\n\n\n\n
        • altered reward processing.<\/li>\n<\/ul>\n\n\n\n

          Longitudinal MRI studies have found persistent alterations involving the brainstem, pre- and postcentral gyri and limbic\/olfactory networks nearly two years after infection.\u00b9\u00b2<\/p>\n\n\n\n

          These findings do not establish that every depressed Long COVID patient has these abnormalities.<\/p>\n\n\n\n

          They do, however, reinforce the idea that the neurological consequences of COVID can persist long after the respiratory disease has disappeared.<\/p>\n\n\n\n

          \n\n\n\n
          VIII. The Brainstem and the Autonomic Nervous System<\/h5>\n\n\n\n

          Another potentially important structure is the brainstem.<\/p>\n\n\n\n

          The brainstem contains nuclei involved in respiration, cardiovascular regulation, arousal, sleep and autonomic control.<\/p>\n\n\n\n

          A 7-Tesla MRI study of COVID survivors identified altered magnetic susceptibility in the medulla, pons and midbrain, including the inferior medullary reticular formation and raphe nuclei. The abnormalities correlated with inflammatory markers, acute disease severity and functional recovery.\u00b9\u00b3<\/p>\n\n\n\n

          This becomes especially interesting when considered alongside Long COVID dysautonomia.<\/p>\n\n\n\n

          A patient with autonomic dysfunction may experience:<\/p>\n\n\n\n

            \n
          • tachycardia;<\/li>\n\n\n\n
          • orthostatic intolerance;<\/li>\n\n\n\n
          • dizziness;<\/li>\n\n\n\n
          • sweating abnormalities;<\/li>\n\n\n\n
          • temperature dysregulation;<\/li>\n\n\n\n
          • gastrointestinal dysfunction;<\/li>\n\n\n\n
          • sleep disruption;<\/li>\n\n\n\n
          • exercise intolerance.<\/li>\n<\/ul>\n\n\n\n

            Living inside such a physiological state for months can itself profoundly alter mood.<\/p>\n\n\n\n

            The relationship may therefore be bidirectional:<\/p>\n\n\n\n

            brainstem\/autonomic dysfunction \u2192 depression<\/strong><\/p>\n\n\n\n

            while<\/p>\n\n\n\n

            depression\/anxiety \u2192 increased autonomic activation.<\/strong><\/p>\n\n\n\n

            The result is a self-reinforcing physiological loop.<\/p>\n\n\n\n

            \n\n\n\n
            IX. Cortisol and the Hypothalamic-Pituitary-Adrenal Axis<\/h5>\n\n\n\n

            The hypothalamic-pituitary-adrenal, or HPA, axis<\/strong> is one of the body’s principal systems for responding to physiological stress.<\/p>\n\n\n\n

            Hypothalamus \u2192 pituitary \u2192 adrenal glands \u2192 cortisol.<\/p>\n\n\n\n

            Cortisol affects:<\/p>\n\n\n\n

              \n
            • metabolism;<\/li>\n\n\n\n
            • immune regulation;<\/li>\n\n\n\n
            • blood pressure;<\/li>\n\n\n\n
            • sleep-wake rhythms;<\/li>\n\n\n\n
            • cognition;<\/li>\n\n\n\n
            • emotional processing.<\/li>\n<\/ul>\n\n\n\n

              Long COVID studies have identified abnormalities in cortisol and other endocrine signals, although results are inconsistent.<\/p>\n\n\n\n

              One 2026 review concluded that lower cortisol is frequently associated with fatigue, sensory symptoms and neurocognitive problems, while abnormalities involving ACTH and other hormones suggest HPA-axis involvement in at least a subset of patients.\u00b9\u2074<\/p>\n\n\n\n

              Another study found biochemical evidence of possible adrenal insufficiency in approximately 14% of recovered patients three months after COVID, although abnormalities appeared transient and resolved in those followed to one year.\u00b9\u2075<\/p>\n\n\n\n

              These findings illustrate an important principle:<\/p>\n\n\n\n

              Long COVID biology is dynamic.<\/strong><\/p>\n\n\n\n

              The endocrine system may be profoundly abnormal during one phase and substantially recover during another.<\/p>\n\n\n\n

              This may help explain why depression itself can wax and wane.<\/p>\n\n\n\n

              \n\n\n\n
              X. Sleep: The Hidden Accelerator<\/h5>\n\n\n\n

              Sleep deserves considerably more attention than it receives.<\/p>\n\n\n\n

              Sleep disturbance is among the most common manifestations of Long COVID. A large systematic review estimated sleep disorders in approximately 45%<\/strong> of people with post-COVID syndrome.\u00b2<\/p>\n\n\n\n

              Sleep deprivation itself can produce:<\/p>\n\n\n\n

                \n
              • depressed mood;<\/li>\n\n\n\n
              • irritability;<\/li>\n\n\n\n
              • cognitive impairment;<\/li>\n\n\n\n
              • impaired emotional regulation;<\/li>\n\n\n\n
              • reduced motivation;<\/li>\n\n\n\n
              • anxiety;<\/li>\n\n\n\n
              • impaired executive function.<\/li>\n<\/ul>\n\n\n\n

                Consequently, a patient may enter a vicious cycle:<\/p>\n\n\n\n

                COVID \u2192 autonomic dysfunction \u2192 insomnia \u2192 fatigue \u2192 cognitive dysfunction \u2192 loss of function \u2192 depression \u2192 worse sleep \u2192 worse cognition.<\/strong><\/p>\n\n\n\n

                In some patients, the psychiatric component may therefore be less a separate disease than the psychological expression of a continuously disturbed neurophysiological system.<\/p>\n\n\n\n

                \n\n\n\n
                XI. The Physical Burden of Long COVID as a Driver of Depression<\/h5>\n\n\n\n

                Biology does not eliminate psychology.<\/p>\n\n\n\n

                It explains why psychology and physiology can become inseparable.<\/p>\n\n\n\n

                Imagine a person who once worked eight hours a day, exercised, drove, socialized and planned for the future.<\/p>\n\n\n\n

                After COVID, that person may become unable to walk more than a few hundred yards without tachycardia. They may forget conversations, lose words, sleep badly and experience neuropathic pain.<\/p>\n\n\n\n

                Eventually they stop working.<\/p>\n\n\n\n

                Then they stop driving.<\/p>\n\n\n\n

                Then they stop seeing friends.<\/p>\n\n\n\n

                The depression that follows is real.<\/p>\n\n\n\n

                But it is not necessarily the original cause.<\/p>\n\n\n\n

                It may be the consequence of a neurological disease that has progressively dismantled the person’s former life.<\/p>\n\n\n\n

                This distinction is crucial clinically because telling such patients simply to “think positively” is not treatment.<\/p>\n\n\n\n

                \n\n\n\n
                XII. The Human Stories Behind the Statistics<\/h5>\n\n\n\n

                Scientific papers provide averages.<\/p>\n\n\n\n

                Patients provide the human meaning of those averages.<\/p>\n\n\n\n

                Hannah Davis<\/h5>\n\n\n\n

                In a 2025 Washington Post<\/em> account, Hannah Davis described becoming ill in March 2020. Her respiratory symptoms were relatively mild, but neurological dysfunction emerged rapidly.<\/p>\n\n\n\n

                Before infection, her processing-speed score had been in the 96th percentile<\/strong>.<\/p>\n\n\n\n

                After COVID, it fell to the 14th percentile<\/strong>.<\/p>\n\n\n\n

                She described losing the continuous flow of ideas that had characterized her creative life.<\/p>\n\n\n\n

                Five years later, her brain had still not returned to baseline, although she had regained abilities such as driving and playing video games. She subsequently became a prominent Long COVID researcher and co-founded the Patient-Led Research Collaborative.\u00b9\u2076<\/p>\n\n\n\n

                Her story illustrates an important distinction between recovery<\/em> and adaptation<\/em>.<\/p>\n\n\n\n

                A person may recover enough function to resume parts of life without returning to their previous neurological baseline.<\/p>\n\n\n\n

                That distinction is particularly important when evaluating depression.<\/p>\n\n\n\n

                \n\n\n\n
                Janna Moen<\/h5>\n\n\n\n

                Janna Moen, a neuroscientist, developed Long COVID after an infection in March 2020.<\/p>\n\n\n\n

                She developed autonomic dysfunction, neuropathic sensations, temperature dysregulation, severe sweating and episodes of near-fainting.<\/p>\n\n\n\n

                Following another infection, her neurological symptoms worsened dramatically, with severe confusion and disorientation.<\/p>\n\n\n\n

                She ultimately had to leave her first postdoctoral position.<\/p>\n\n\n\n

                Years later she remained substantially disabled, although she was able to work and was studying the neuroimmune basis of Long COVID herself.\u00b9\u2076<\/p>\n\n\n\n

                Her story demonstrates how depression can arise in an environment of persistent neurological dysfunction without being reducible to it.<\/p>\n\n\n\n

                \n\n\n\n
                Wachuka Gichohi<\/h5>\n\n\n\n

                Reuters profiled Kenyan businesswoman Wachuka Gichohi after four years of Long COVID.<\/p>\n\n\n\n

                Her illness included debilitating fatigue, pain and panic attacks so severe that she feared she might die during the night.<\/p>\n\n\n\n

                She described becoming frustrated by expressions such as “feel better soon,” because after four years she no longer believed conventional recovery was imminent.<\/p>\n\n\n\n

                Her eventual psychological adaptation was not simply “getting better.”<\/p>\n\n\n\n

                She described changing her objective from chasing recovery<\/em> to learning to live within the limitations imposed by chronic illness.\u00b9\u2077<\/p>\n\n\n\n

                That distinction has considerable relevance to depression.<\/p>\n\n\n\n

                Sometimes recovery of the brain and recovery of the life are different processes.<\/p>\n\n\n\n

                \n\n\n\n
                Leticia Soares<\/h5>\n\n\n\n

                Leticia Soares of Brazil was infected in 2020 and, according to Reuters, continued to experience severe fatigue and chronic pain years later.<\/p>\n\n\n\n

                On a good day she spent only about five hours out of bed.<\/p>\n\n\n\n

                She described the disease as profoundly disabling and isolating and worried continuously about deterioration.\u00b9\u2077<\/p>\n\n\n\n

                Her story demonstrates the psychological burden of uncertainty<\/strong>.<\/p>\n\n\n\n

                Depression is not only about suffering today.<\/p>\n\n\n\n

                It can arise from an inability to predict tomorrow.<\/p>\n\n\n\n

                \n\n\n\n
                Shannon Turner<\/h5>\n\n\n\n

                Shannon Turner, a Philadelphia cabaret singer, developed Long COVID in 2020 and subsequently experienced profound fatigue, pain, dizziness and tachycardia.<\/p>\n\n\n\n

                After another COVID infection, the symptoms again worsened and she required a walker.<\/p>\n\n\n\n

                Yet she remained determined to pursue her music career.<\/p>\n\n\n\n

                “I don’t want to live my life in bed,” she told Reuters.\u00b9\u2077<\/p>\n\n\n\n

                Turner’s story illustrates an important phenomenon in chronic illness: resilience and depression can coexist.<\/p>\n\n\n\n

                A patient may be severely depressed at one point and fiercely determined at another.<\/p>\n\n\n\n

                The two states are not mutually exclusive.<\/p>\n\n\n\n

                \n\n\n\n
                A Story of Gradual Improvement<\/h5>\n\n\n\n

                A British Long COVID patient identified by The Guardian<\/em> as Willis described becoming so exhausted that she slept nine or ten hours a day and could not shop, drive normally or manage ordinary household responsibilities.<\/p>\n\n\n\n

                She underwent breathing physiotherapy, joined a patient group, received antidepressant treatment and attempted several complementary approaches. The social component of the rehabilitation was itself important because patients found the invisible nature of their disease profoundly isolating.\u00b9\u2078<\/p>\n\n\n\n

                Her story is important because it demonstrates that improvement is possible.<\/p>\n\n\n\n

                Long COVID should not be portrayed as inevitably permanent.<\/p>\n\n\n\n

                Some patients recover substantially.<\/p>\n\n\n\n

                Others recover partially.<\/p>\n\n\n\n

                Some plateau.<\/p>\n\n\n\n

                Some relapse.<\/p>\n\n\n\n

                And some remain severely disabled for years.<\/p>\n\n\n\n

                The scientific challenge is to understand why.<\/p>\n\n\n\n

                \n\n\n\n
                XIII. How Long Does the Depression Last?<\/h5>\n\n\n\n

                The answer is: there is no single course.<\/strong><\/p>\n\n\n\n

                Some patients experience depressive symptoms for several weeks.<\/p>\n\n\n\n

                Others remain symptomatic for six months.<\/p>\n\n\n\n

                A substantial minority continue to experience depression or related psychiatric symptoms for one or two years.<\/p>\n\n\n\n

                Still others have recurrent symptoms associated with relapses of their physical Long COVID.<\/p>\n\n\n\n

                The best longitudinal evidence suggests an overall decline in depression prevalence with time, but not a universal or linear recovery.\u00b3<\/p>\n\n\n\n

                The broader Long COVID trajectory is similarly heterogeneous.<\/p>\n\n\n\n

                Reuters reported that the probability of full recovery appears greatest during the first six months and becomes progressively smaller in patients whose illness persists for years, although the exact recovery probability varies markedly between studies and patient populations.\u00b9\u2077<\/p>\n\n\n\n

                This does not<\/strong> mean that a patient who remains ill after two years has no chance of improvement.<\/p>\n\n\n\n

                It means that prolonged illness represents a different clinical phenotype and should not simply be regarded as acute COVID taking an unusually long time to disappear.<\/p>\n\n\n\n

                \n\n\n\n
                XIV. Depression May Become More Severe When Physical Symptoms Accumulate<\/h5>\n\n\n\n

                One of the most consistent observations is that psychiatric burden rises with the number and severity of physical symptoms.<\/p>\n\n\n\n

                A study of post-COVID depression found that the number of persistent post-COVID symptoms predicted the presence of depression, while the number of acute symptoms predicted depression severity.\u00b9\u00b9<\/p>\n\n\n\n

                This suggests a model in which depression is not an isolated complication.<\/p>\n\n\n\n

                Rather:<\/p>\n\n\n\n

                more biological systems become dysfunctional \u2192 greater disability \u2192 greater neurological burden \u2192 greater psychiatric burden.<\/strong><\/p>\n\n\n\n

                That model also explains why depression can improve when physical function improves.<\/p>\n\n\n\n

                \n\n\n\n
                XV. Depression and Brain Fog Are Closely Intertwined<\/h5>\n\n\n\n

                Depression and cognitive dysfunction frequently coexist.<\/p>\n\n\n\n

                The patient may say:<\/p>\n\n\n\n

                \n

                “I can’t think.”<\/p>\n<\/blockquote>\n\n\n\n

                But what does that mean?<\/p>\n\n\n\n

                It may mean:<\/p>\n\n\n\n

                  \n
                • slowed processing speed;<\/li>\n\n\n\n
                • impaired working memory;<\/li>\n\n\n\n
                • difficulty retrieving words;<\/li>\n\n\n\n
                • impaired attention;<\/li>\n\n\n\n
                • executive dysfunction;<\/li>\n\n\n\n
                • inability to multitask;<\/li>\n\n\n\n
                • poor sleep;<\/li>\n\n\n\n
                • depression;<\/li>\n\n\n\n
                • autonomic dysfunction;<\/li>\n\n\n\n
                • fatigue.<\/li>\n<\/ul>\n\n\n\n

                  Or, more commonly, several of these simultaneously.<\/p>\n\n\n\n

                  A systematic review of 17 studies involving more than 41,000 Long COVID patients found that approximately one-fifth had either mental health conditions or brain fog across follow-up periods of three to 24 months.\u00b9\u2079<\/p>\n\n\n\n

                  The clinical implication is obvious:<\/p>\n\n\n\n

                  depression should be evaluated alongside cognition rather than in isolation.<\/strong><\/p>\n\n\n\n

                  \n\n\n\n
                  XVI. Treatment: What Actually Helps?<\/h5>\n\n\n\n

                  Treatment remains frustratingly incomplete.<\/p>\n\n\n\n

                  There is no universally effective Long COVID antidepressant and no FDA-approved drug specifically for Long COVID depression.<\/p>\n\n\n\n

                  Nevertheless, several therapeutic approaches have evidence.<\/p>\n\n\n\n

                  1. Conventional antidepressant treatment<\/h5>\n\n\n\n

                  Antidepressants remain appropriate when a patient meets criteria for major depressive disorder.<\/p>\n\n\n\n

                  A study of 60 patients with post-COVID major depressive episodes reported an unusually high response rate to SSRIs: 55 of 60 patients\u2014approximately 92%\u2014met criteria for clinical response after four weeks<\/strong>. Hamilton Depression Rating Scale scores fell from approximately 23 to approximately 7.\u00b2\u2070<\/p>\n\n\n\n

                  The study was not randomized and should therefore not be interpreted as proof that SSRIs work in 92% of all Long COVID patients.<\/p>\n\n\n\n

                  But the magnitude of improvement is clinically interesting.<\/p>\n\n\n\n

                  A larger observational study of 116 patients with post-COVID major depressive episodes found significant improvement in depression, anxiety, physical symptoms, cognitive symptoms and inflammatory indices during three months of antidepressant treatment.\u00b2\u00b9<\/p>\n\n\n\n

                  \n\n\n\n
                  XVII. Vortioxetine: Depression and Cognition<\/h5>\n\n\n\n

                  Vortioxetine has received particular interest because it possesses both antidepressant and cognitive effects.<\/p>\n\n\n\n

                  In a randomized controlled trial of people with post-COVID condition, vortioxetine produced significant improvements in depressive symptoms and quality of life.\u00b2\u00b2<\/p>\n\n\n\n

                  A subsequent analysis found that improvement in depressive symptoms was particularly related to improvement in anxiety, suggesting that treating the emotional network rather than depression in isolation may be important.\u00b2\u00b3<\/p>\n\n\n\n

                  Vortioxetine is therefore intriguing for patients in whom depression and cognitive complaints coexist, although it is not established as a universal Long COVID treatment.<\/p>\n\n\n\n

                  \n\n\n\n
                  XVIII. Psychotherapy: Necessary, but Not Because Long COVID Is “All in the Head”<\/h5>\n\n\n\n

                  Psychological treatment can be valuable without implying that the underlying illness is psychological.<\/p>\n\n\n\n

                  A 2026 systematic review and meta-analysis of psychological interventions for Long COVID found significant reductions in depression, anxiety and fatigue, with improvements in perceived health-related quality of life.\u00b2\u2074<\/p>\n\n\n\n

                  Interestingly, however, not every trial has been positive.<\/p>\n\n\n\n

                  A 2026 randomized study of group psychotherapy specifically designed for post-COVID patients did not<\/strong> demonstrate a statistically significant advantage over treatment as usual for depression, anxiety or overall somatic symptom burden.\u00b2\u2075<\/p>\n\n\n\n

                  This apparent contradiction is instructive.<\/p>\n\n\n\n

                  Psychotherapy can help people cope with chronic illness, but it should not be expected to reverse every biological mechanism responsible for Long COVID.<\/p>\n\n\n\n

                  \n\n\n\n
                  XIX. Rehabilitation Can Improve Depression by Improving the Whole System<\/h5>\n\n\n\n

                  Physical and cognitive rehabilitation may indirectly improve depression by restoring function.<\/p>\n\n\n\n

                  A randomized rehabilitation trial found that symptom-based rehabilitation improved post-COVID symptom burden and produced significant improvements in mental health quality of life, depression and anxiety.\u00b2\u2076<\/p>\n\n\n\n

                  This supports an important therapeutic principle:<\/p>\n\n\n\n

                  sometimes the best antidepressant is not directed exclusively at mood.<\/strong><\/p>\n\n\n\n

                  Restoring sleep, mobility, cognitive function, social connection and physiological stability can reduce depression by restoring pieces of the patient’s former life.<\/p>\n\n\n\n

                  However, rehabilitation must be individualized.<\/p>\n\n\n\n

                  Patients with post-exertional malaise may worsen with inappropriate graded exercise, making pacing and careful symptom monitoring essential.<\/p>\n\n\n\n

                  \n\n\n\n
                  XX. Anti-inflammatory Treatment: An Intriguing but Unsettled Area<\/h5>\n\n\n\n

                  The inflammatory theory of post-COVID depression has encouraged trials of anti-inflammatory therapies.<\/p>\n\n\n\n

                  One randomized controlled study examined celecoxib in patients with moderate depressive symptoms following COVID-19 and reported substantially greater reductions in depression scores than placebo, with unusually high response and remission rates.\u00b2\u2077<\/p>\n\n\n\n

                  The results are provocative.<\/p>\n\n\n\n

                  They are not sufficient to establish celecoxib as standard treatment.<\/p>\n\n\n\n

                  The trial was relatively small, and larger studies with longer follow-up are required.<\/p>\n\n\n\n

                  Nevertheless, it raises an important possibility:<\/p>\n\n\n\n

                  in some patients, post-COVID depression may be unusually sensitive to modulation of inflammatory pathways.<\/strong><\/p>\n\n\n\n

                  \n\n\n\n
                  XXI. The Emerging SSRI\u2013Long COVID Connection<\/h5>\n\n\n\n

                  An especially interesting development concerns whether SSRIs might influence Long COVID itself rather than simply treat its depression.<\/p>\n\n\n\n

                  A large observational study involving more than 300,000 people with pre-existing depression<\/strong> found that patients taking SSRIs during acute COVID had a modestly lower subsequent risk of Long COVID.\u00b2\u2078<\/p>\n\n\n\n

                  A newer 2026 analysis involving more than 500,000 patients<\/strong> similarly found associations between SSRI treatment and reduced risk of several categories of post-COVID symptoms.\u00b2\u2079<\/p>\n\n\n\n

                  These studies are observational.<\/p>\n\n\n\n

                  They cannot prove that SSRIs prevent Long COVID.<\/p>\n\n\n\n

                  But combined with the serotonin findings, they make an increasingly coherent biological hypothesis worthy of randomized trials.<\/p>\n\n\n\n

                  \n\n\n\n
                  XXII. What Depression Looks Like in Long COVID<\/h5>\n\n\n\n

                  The phenotype can differ from classic depression.<\/p>\n\n\n\n

                  Patients may report:<\/p>\n\n\n\n

                  Anhedonia:<\/strong>
                  “I don’t enjoy anything anymore.”<\/p>\n\n\n\n

                  Cognitive exhaustion:<\/strong>
                  “My brain simply stops working.”<\/p>\n\n\n\n

                  Psychomotor slowing:<\/strong>
                  “Everything takes enormous effort.”<\/p>\n\n\n\n

                  Emotional blunting:<\/strong>
                  “I don’t feel sad. I just don’t feel anything.”<\/p>\n\n\n\n

                  Loss of future orientation:<\/strong>
                  “I cannot imagine my life getting better.”<\/p>\n\n\n\n

                  Sleep fragmentation:<\/strong>
                  “I am exhausted all day but cannot sleep normally.”<\/p>\n\n\n\n

                  Anxiety and autonomic symptoms:<\/strong>
                  “My heart races and I feel like something terrible is happening.”<\/p>\n\n\n\n

                  Physical hopelessness:<\/strong>
                  “I don’t know how I can live like this.”<\/p>\n\n\n\n

                  This mixture is one reason Long COVID depression can be difficult to classify.<\/p>\n\n\n\n

                  It may contain elements of:<\/p>\n\n\n\n

                    \n
                  • major depressive disorder;<\/li>\n\n\n\n
                  • anxiety;<\/li>\n\n\n\n
                  • PTSD;<\/li>\n\n\n\n
                  • illness-related demoralization;<\/li>\n\n\n\n
                  • neuroinflammation;<\/li>\n\n\n\n
                  • autonomic dysfunction;<\/li>\n\n\n\n
                  • sleep disorder;<\/li>\n\n\n\n
                  • cognitive impairment.<\/li>\n<\/ul>\n\n\n\n

                    The diagnostic categories overlap.<\/p>\n\n\n\n

                    \n\n\n\n
                    XXIII. A Unified Model<\/h5>\n\n\n\n

                    The emerging evidence can be assembled into a hypothetical biological model:<\/p>\n\n\n\n

                    SARS-CoV-2 infection<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    persistent immune activation \/ viral remnants \/ tissue injury<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    interferon signaling + cytokine activation<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    microglial and astrocytic activation<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    blood-brain barrier and vascular dysfunction<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    altered cerebral perfusion<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    white-matter and gray-matter abnormalities<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    altered tryptophan\u2013kynurenine metabolism<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    altered serotonin availability<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    autonomic and vagal dysfunction<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    HPA-axis disturbance<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    sleep disruption + fatigue + cognitive dysfunction<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    loss of physical and social function<\/strong><\/p>\n\n\n\n

                    \u2193<\/p>\n\n\n\n

                    DEPRESSION<\/strong><\/h5>\n\n\n\n

                    The arrows should not be interpreted as a proven linear pathway.<\/p>\n\n\n\n

                    They represent interacting biological systems.<\/p>\n\n\n\n

                    Some patients may begin with immune dysfunction.<\/p>\n\n\n\n

                    Others may have autonomic dysfunction.<\/p>\n\n\n\n

                    Others may have sleep disruption or persistent inflammation.<\/p>\n\n\n\n

                    Others may primarily develop depression in response to disability.<\/p>\n\n\n\n

                    Long COVID is probably not one disease.<\/p>\n\n\n\n

                    It is a collection of overlapping biological phenotypes.<\/p>\n\n\n\n

                    \n\n\n\n
                    XXIV. The Most Important Scientific Question<\/h5>\n\n\n\n

                    The most important unanswered question may not be:<\/p>\n\n\n\n

                    “Does COVID cause depression?”<\/strong><\/p>\n\n\n\n

                    The evidence increasingly supports the conclusion that COVID can increase the risk of depressive illness.<\/p>\n\n\n\n

                    The more important question is:<\/p>\n\n\n\n

                    “Which patients develop biologically mediated depression, through which pathways, and why do some recover while others remain ill for years?”<\/strong><\/p>\n\n\n\n

                    That question is considerably more difficult.<\/p>\n\n\n\n

                    It requires longitudinal studies combining:<\/p>\n\n\n\n

                      \n
                    • psychiatric assessment;<\/li>\n\n\n\n
                    • neuropsychological testing;<\/li>\n\n\n\n
                    • quantitative MRI;<\/li>\n\n\n\n
                    • PET imaging;<\/li>\n\n\n\n
                    • inflammatory biomarkers;<\/li>\n\n\n\n
                    • kynurenine metabolites;<\/li>\n\n\n\n
                    • serotonin measurements;<\/li>\n\n\n\n
                    • cortisol;<\/li>\n\n\n\n
                    • autonomic testing;<\/li>\n\n\n\n
                    • sleep studies;<\/li>\n\n\n\n
                    • immune-cell profiling;<\/li>\n\n\n\n
                    • viral persistence measurements;<\/li>\n\n\n\n
                    • metabolic analysis;<\/li>\n\n\n\n
                    • genetic susceptibility.<\/li>\n<\/ul>\n\n\n\n

                      The future of Long COVID psychiatry will probably not be a single diagnostic category called “post-COVID depression.”<\/p>\n\n\n\n

                      It will be biologically stratified psychiatry<\/strong>.<\/p>\n\n\n\n

                      One patient may have inflammation-dominant disease.<\/p>\n\n\n\n

                      Another may have autonomic-dominant disease.<\/p>\n\n\n\n

                      Another may have metabolic or mitochondrial dysfunction.<\/p>\n\n\n\n

                      Another may have persistent viral antigen.<\/p>\n\n\n\n

                      Another may have predominantly psychological consequences of catastrophic physical disability.<\/p>\n\n\n\n

                      And many will have combinations of all of these.<\/p>\n\n\n\n

                      \n\n\n\n
                      XXV. Recovery: The More Hopeful Part of the Story<\/h5>\n\n\n\n

                      The darkest accounts of Long COVID can create the impression that recovery never occurs.<\/p>\n\n\n\n

                      That is incorrect.<\/p>\n\n\n\n

                      Many patients improve substantially.<\/p>\n\n\n\n

                      Some recover within months.<\/p>\n\n\n\n

                      Others require a year or longer.<\/p>\n\n\n\n

                      Some experience partial recovery followed by relapse.<\/p>\n\n\n\n

                      Others develop a chronic illness that requires adaptation.<\/p>\n\n\n\n

                      The scientific literature increasingly suggests that recovery is heterogeneous rather than binary<\/strong>.<\/p>\n\n\n\n

                      A patient who can return to work but cannot exercise as before has recovered something.<\/p>\n\n\n\n

                      A patient who can drive again but cannot tolerate prolonged concentration has recovered something.<\/p>\n\n\n\n

                      A patient whose depression disappears while fatigue remains has recovered something.<\/p>\n\n\n\n

                      Recovery should therefore be measured in dimensions rather than as a single yes\/no outcome.<\/p>\n\n\n\n

                      The Washington Post account of Hannah Davis is instructive: she regained important abilities while continuing to experience substantial neurological impairment years later.\u00b9\u2076<\/p>\n\n\n\n

                      The Reuters accounts of Gichohi and Soares illustrate another form of recovery\u2014psychological adaptation to chronic disease even when biological recovery remains incomplete.\u00b9\u2077<\/p>\n\n\n\n

                      And clinical studies show that depression itself can respond substantially to conventional psychiatric treatment, rehabilitation and psychological intervention even when the underlying Long COVID persists.\u00b2\u2070\u2013\u00b2\u2076<\/p>\n\n\n\n

                      \n\n\n\n
                      XXVI. Conclusion: Depression as a Window Into Long COVID<\/h5>\n\n\n\n

                      The depression associated with Long COVID should no longer be dismissed as merely an understandable emotional response to prolonged illness.<\/p>\n\n\n\n

                      Nor should every case be interpreted as evidence of direct viral injury to the brain.<\/p>\n\n\n\n

                      Both extremes are inadequate.<\/p>\n\n\n\n

                      The evidence instead points toward a complicated interaction between immune activation, neuroinflammation, altered tryptophan and serotonin metabolism, microglial activity, vascular dysfunction, autonomic disturbance, endocrine abnormalities, sleep disruption, cognitive impairment and the psychological consequences of chronic disability.<\/strong><\/p>\n\n\n\n

                      The emerging neuroimaging literature makes the story especially compelling.<\/p>\n\n\n\n

                      In selected patients, the post-COVID depressive state is associated with measurable abnormalities involving white matter, the hippocampus, amygdala, basal ganglia and other neural structures.\u00b9\u00b9\u2013\u00b9\u00b3<\/p>\n\n\n\n

                      The metabolic literature adds another layer: abnormalities in the kynurenine pathway appear to correlate with depression, fatigue and brain changes.\u2076\u2013\u2079<\/p>\n\n\n\n

                      The clinical literature adds another: depression can persist for months or years, but it can also improve, sometimes dramatically, with treatment.\u00b2\u2070\u2013\u00b2\u2076<\/p>\n\n\n\n

                      And the stories of survivors add something that statistics cannot provide.<\/p>\n\n\n\n

                      They show what these numbers mean when translated into a human life.<\/p>\n\n\n\n

                      A person who once created music loses the ability to think.<\/p>\n\n\n\n

                      A scientist becomes unable to walk across a subway platform without nearly fainting.<\/p>\n\n\n\n

                      A businesswoman becomes frightened by the phrase “feel better soon.”<\/p>\n\n\n\n

                      A singer who requires a walker nevertheless refuses to surrender her career.<\/p>\n\n\n\n

                      A parent who cannot shop or drive begins the long process of rebuilding an ordinary life.<\/p>\n\n\n\n

                      These are not simply stories of depression.<\/p>\n\n\n\n

                      They are stories of a nervous system attempting to recover from an infection whose consequences may extend far beyond the respiratory tract.<\/p>\n\n\n\n

                      The most hopeful interpretation of the emerging science is therefore not that every patient will recover spontaneously.<\/p>\n\n\n\n

                      It is that the biology is becoming visible.<\/p>\n\n\n\n

                      And once the biology becomes visible, depression can cease to be merely a mysterious psychological aftermath of COVID-19 and become what it may actually be in many patients:<\/p>\n\n\n\n

                      a measurable manifestation of a systemic neuroimmune disease\u2014one that can be studied, stratified and, eventually, treated according to its underlying mechanism.<\/strong><\/p>\n\n\n\n

                      \n\n\n\n
                      References and Notes<\/h5>\n\n\n\n

                      1.<\/strong> Bidhendi-Yarandi A, et al. Prevalence of depression, anxiety, stress, and suicide tendency among individual with long-COVID and determinants: A systematic review and meta-analysis.<\/em> 2025. Ninety-four studies; pooled depression prevalence approximately 25%, with a gradual decline over time but persistent symptoms in a substantial minority.<\/p>\n\n\n\n

                      2.<\/strong> Chen et al. The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis.<\/em> BMC Psychiatry.<\/em> 2024. Depression\/anxiety approximately 23%; sleep disorders approximately 45%.<\/p>\n\n\n\n

                      3.<\/strong> Changes in prevalence of anxiety and depression among COVID-19 patients during a two-year recovery period: A systematic review and meta-analysis.<\/em> 34 longitudinal cohort studies. Depression prevalence declined from approximately 22% during the first month to approximately 9% at 12\u201324 months, with an intermediate increase at 3\u20136 months.<\/p>\n\n\n\n

                      4.<\/strong> The Impact of Long COVID-19 on Mental Health: Observational 6-Month Follow-Up Study.<\/em> 239 patients. Depression symptoms were reported by 46.9% at three months and 40.6% at six months.<\/p>\n\n\n\n

                      5.<\/strong> Mingoti MED, et al. COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route.<\/em> Journal of Molecular Neuroscience.<\/em> 2022.<\/p>\n\n\n\n

                      6.<\/strong> Maes M, et al. Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in long COVID.<\/em> 2023.<\/p>\n\n\n\n

                      7.<\/strong> Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress.<\/em> 2022.<\/p>\n\n\n\n

                      8.<\/strong> Almulla AF, et al. The tryptophan catabolite or kynurenine pathway in long COVID disease: A systematic review and meta-analysis.<\/em> Neuroscience.<\/em> 2024.<\/p>\n\n\n\n

                      9.<\/strong> Matits L, et al. Cerebral gray matter volumes in long-term post-COVID patients are associated with peripheral kynurenine pathway metabolites and the severity of depressive symptoms.<\/em> Brain, Behavior, and Immunity.<\/em> 2026.<\/p>\n\n\n\n

                      10.<\/strong> Wong AC, et al. Serotonin reduction in post-acute sequelae of viral infection.<\/em> 2023.<\/p>\n\n\n\n

                      11.<\/strong> Demyelination in Patients with POST-COVID Depression.<\/em> 2024. Quantitative MRI identified extensive white- and gray-matter abnormalities, with inferior fronto-occipital fasciculus abnormalities strongly associated with depression severity.<\/p>\n\n\n\n

                      12.<\/strong> Two-year impact of COVID-19: Longitudinal MRI brain changes and neuropsychiatric trajectories.<\/em> 2025. Longitudinal neuroimaging study examining patients approximately 23 months after infection.<\/p>\n\n\n\n

                      13.<\/strong> Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations.<\/em> 2024. Brainstem abnormalities were associated with inflammatory markers, disease severity and functional outcome.<\/p>\n\n\n\n

                      14.<\/strong> Hormonal, metabolic and metabolomic biomarkers in long COVID.<\/em> 2026 review of cortisol, HPA-axis, metabolic and kynurenine-pathway abnormalities.<\/p>\n\n\n\n

                      15.<\/strong> Hypothalamic-Pituitary Adrenal Axis Status 3 Months After Recovery From COVID-19 Infection.<\/em> 2023.<\/p>\n\n\n\n

                      16.<\/strong> Richard Sima. \u201c\u2018Something was wrong with my brain\u2019: How covid leaves its mark on cognition.\u201d The Washington Post<\/em>, March 27, 2025. Patient accounts of Hannah Davis and Janna Moen and review of neurological research.<\/p>\n\n\n\n

                      17.<\/strong> Jennifer Rigby and Julie Steenhuysen. \u201cMany long COVID patients adjust to slim recovery odds as world moves on.\u201d Reuters<\/em>, November 15, 2024. Patient accounts of Wachuka Gichohi, Leticia Soares and Shannon Turner.<\/p>\n\n\n\n

                      18.<\/strong> The Guardian.<\/em> \u201c\u2018I\u2019m going to get there\u2019: the slow path to recovery from long Covid.\u201d 2022. Patient account describing prolonged fatigue, antidepressant treatment, rehabilitation and gradual adaptation.<\/p>\n\n\n\n

                      19.<\/strong> Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis.<\/em> 2024. Seventeen studies involving 41,249 Long COVID patients.<\/p>\n\n\n\n

                      20.<\/strong> Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.<\/em> 60 patients; 55 demonstrated clinical response after four weeks.<\/p>\n\n\n\n

                      21.<\/strong> Physical and cognitive correlates, inflammatory levels, and treatment response in post-COVID-19 first-onset vs. recurrent depressive episodes.<\/em> 116 patients; antidepressant treatment was associated with improvement in depression, anxiety, physical and cognitive symptoms and inflammatory measures.<\/p>\n\n\n\n

                      22.<\/strong> Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.<\/em> Significant improvement in depressive symptoms and quality of life.<\/p>\n\n\n\n

                      23.<\/strong> Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition.<\/em> 2024.<\/p>\n\n\n\n

                      24.<\/strong> Garriga-Salv\u00f3 C, et al. Psychological interventions for individuals with long COVID: a systematic review and meta-analysis.<\/em> Health Psychology Review.<\/em> 2026.<\/p>\n\n\n\n

                      25.<\/strong> Efficacy of a psychotherapeutic group intervention for patients with Post-COVID-19 condition: the PsyLoCo study.<\/em> 2026 randomized controlled trial.<\/p>\n\n\n\n

                      26.<\/strong> Symptom-based rehabilitation in people with post-COVID-19 condition (RELOAD study): a randomised controlled trial.<\/em> 2026. Rehabilitation significantly improved depression, anxiety and mental health quality of life in addition to overall post-COVID symptom burden.<\/p>\n\n\n\n

                      27.<\/strong> Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: a randomized, double-blind, placebo-controlled trial.<\/em> 2023. Promising but requiring replication before clinical adoption specifically for post-COVID depression.<\/p>\n\n\n\n

                      28.<\/strong> SSRI use during acute COVID-19 and risk of long COVID among patients with depression.<\/em> Large N3C observational cohort of 302,626 patients.<\/p>\n\n\n\n

                      29.<\/strong> 2026 electronic-health-record study of 542,938 patients with depression examining SSRI exposure and subsequent Long COVID-associated symptoms. Observational associations support, but do not prove, a protective effect.<\/p>\n","protected":false},"excerpt":{"rendered":"

                      COVID-19, Long COVID, and the Biology of Persistent Depression John Murphy, CEO The COVID-19 Long haul Foundation Introduction: A Depression That May Not Begin in the Mind Among the many […]<\/p>\n","protected":false},"author":2,"featured_media":15955,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[113,149,289,320,364,523],"tags":[],"class_list":["post-15946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-depression-mental-health","category-epidemiology","category-long-haul-disease","category-microglia","category-neuroinflammation","category-serotonin"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15946"}],"version-history":[{"count":2,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15946\/revisions"}],"predecessor-version":[{"id":15948,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15946\/revisions\/15948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15955"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}